Sevoflurane Market Revenue to Attain USD 2.02 Bn by 2035

Sevoflurane Market Revenue and Trends 2026 to 2035

The global sevoflurane market revenue reached USD 1.15 billion in 2025 and is predicted to attain around USD 2.02 billion by 2035 with a CAGR of 5.80%. The market is driven by the increased number of lifestyle and chronic diseases that require surgery, and the increased use of sevoflurane, which is an anaesthetic drug owing to its favorable attributes such as fast onset and offset, lack of pungency, and good hemodynamic stability.

The Inhalational Anesthetic for Modern Surgery

The sevoflurane market comprises the manufacture, formulation, packaging, and international marketing of sevoflurane, which is a fluorinated ether inhalation anesthetic. It is a volatile liquid utilized for the induction and maintenance of general anesthesia in surgery. Sevoflurane is chosen for the favorable characteristics that it offers, such as rapid onset and recovery, lack of pungency, and good hemodynamic stability with minimal respiratory irritation.

The market involves liquid sevoflurane, which is formulated specifically for use with calibrated vaporizers and generic and branded forms marketed to hospitals, ambulatory surgical centers, and veterinary hospitals. Some of the applications of sevoflurane include cardiothoracic surgery, orthopedics, neurological surgery, and other outpatient surgeries requiring rapid emergence from anesthesia. This market has been adopted by anesthesia departments in hospitals, ambulatory surgical centers, and veterinary centers.

Expansion of Manufacturing Capacity Increases Global Supply of Inhalation Anesthetics

The market is witnessing increased investments in manufacturing capacity by companies to cater to increasing surgical demand. Building up production capacities in diverse regions helps in securing the supply chain and enables companies to reach out to mature and developing markets equally. In 2025, Piramal Pharma launched the commercial production of sevoflurane at its manufacturing facility in Digwal, Telangana, India. This is an addition to the company’s current manufacturing facility at Bethlehem, Pennsylvania, U.S. This expansion of manufacturing capacity will enable the company to explore inhalation anesthesia opportunities in the developing markets. 

Veterinary Sevoflurane Market Grows With New FDA-Approved Products

The market is experiencing an increase in the usage of sevoflurane in veterinary medicine, with companies launching FDA-approved products in the companion animal segment. This helps in creating additional revenue sources outside the conventional human surgery sector. Veterinary clinics are now choosing sevoflurane for its quick action and recovery period, which makes it ideal for routine surgeries in dogs and cats. In 2026, Parnell introduced an FDA-approved sevoflurane inhalation anesthetic for dogs following its approval under ANADA #200-830.

Environmental Laws Pertaining to Anesthetic Gases Affecting Hospital Procurement

Regulations regarding anesthetic gases are increasingly becoming common as governments take environmental action plans, thereby putting new regulations in place that affect the market for sevoflurane. Such regulations seek to discover emission sources, conduct research on reduction methods, and eventually limit or ban gases with high emissions, indirectly affecting market trends. In 2025, the Washington State Legislature, U.S., passed Senate Bill 5236 to identify sevoflurane and other anesthetic gases as potent greenhouse gases. The bill stipulates that a study will be conducted to find the extent of emissions and the possible reduction methods, whose results have to be submitted before October 1, 2026.

Canadian Hospitals Reduce Anesthetic Emissions by 52% Through the Use of Sevoflurane

In 2026, Island Health announced a 52% reduction in its usage of desflurane for the year 2025, resulting in a reduction of 275 tons of CO2 emissions and saving roughly USD 24,800 in the cost of anesthetic gases. The Royal Jubilee and West Coast General hospitals managed to reduce their emissions from desflurane by 74% and 75%, respectively. Today, more than 125 hospitals in Canada have stopped using desflurane altogether and switched to sevoflurane.

Market Segmentation Overview

• By product type, the branded sevoflurane segment led the sevoflurane market with 42% share in 2025, because of the priority of clinical confidence, consistency of batches, and safety of the product, which is of extreme importance when it comes to anesthesia for surgery, and due to the strong relationship built by branded suppliers through long-term contracts, compatible vaporizers, and education.
• By product type, the generic sevoflurane segment is expected to expand at the highest CAGR of 7.6% during the forecast period, due to the constant pressure on hospitals’ procurement departments to cut down expenses during the process of treatments. The procurement departments prefer cheaper generic drugs that become available after patent expiry and approval by the FDA in several formulations.
• By formulation, the liquid sevoflurane segment dominated the market with 82% share in 2025, since sevoflurane is a volatile anesthetic that exists in stable liquid form in amber glass containers and is administered using the precision vaporization systems of anesthesia delivery services during the treatment.
• By formulation, the stabilized sevoflurane segment is expected to grow at the fastest CAGR of 7.8% from 2026 to 2035, as it has an increased shelf life and resistance to degradation as compared to liquid sevoflurane, which makes it suitable for hospitals, ambulatory surgical centers, and military units. It makes handling inventories easier, eliminating wastage caused by the expiration of the drug.
• By application, the general surgery segment led the market with 32% share in 2025, due to the fact that it involves the largest number of surgical operations globally, such as appendectomy, hernia repair, gall bladder removal, and bowel surgery. Sevoflurane is most commonly used in general surgery owing to its speedy induction and recovery, non-offensive smell, and excellent cardiovascular stability.
• By application, the ambulatory surgery segment is expected to expand at the highest CAGR of 7.5% during the forecast period, since the recent paradigm shift to outpatient surgeries on account of cost containment strategies, patients’ preference for one-day surgeries, and advances in minimally invasive procedures have rendered sevoflurane as the most favored anesthesia agent.
• By end user, the hospitals segment dominated the sevoflurane market with 68% share in 2025, because sevoflurane is an inhalation anesthetic used solely during surgical procedures in operating rooms, and hospitals are one of the primary places where this anesthetic can be applied by using anesthesia machines and vaporizers. Hospitals are the place where the highest number of operations take place globally, leading to large amounts of consumption of sevoflurane. 
• By end user, the ambulatory surgical centers segment is expected to grow at the fastest CAGR of 7.9% from 2026 to 2035, due to the fact that sevoflurane has become the drug of choice for ambulatory surgical centers worldwide. Patients are preferring outpatient surgical procedures, driven by considerations such as cost savings, patients’ desire to leave the hospital immediately after the operation, and the development of less invasive surgical procedures.
• By distribution channel, the direct tender sales segment led the market with 46% share in 2025, since sevoflurane is a high-value product sold exclusively to medical facilities in bulk purchases made through centralized procurement agreements and government tender processes. This channel allows direct education of the anesthesiology departments in hospitals as well as documentation of regulatory requirements.
• By distribution channel, the online procurement platforms segment is expected to expand at the highest CAGR of 8.8% during the forecast period, because small hospitals, ambulatory surgical centers, and veterinary clinics need to procure sevoflurane in lesser quantities than large hospitals. Online platforms eliminate the need for lengthy contracts and minimum orders that usually come with direct purchases while providing clear pricing, quick supplier comparison, and easy documentation.

Regional Analysis

North America dominated the sevoflurane market with 36% share in 2025, due to the fact that it has the highest number of surgeries in the world, owing to the existence of high-end healthcare infrastructure and widespread adoption of sevoflurane. The U.S. led the market in North America because of the presence of large hospital networks and the adoption of low-flow anesthesia delivery methods for lowering costs and emissions, coupled with the shift from using desflurane to sevoflurane in many medical facilities. Canada witnessed notable market growth owing to its government-backed healthcare system, where there is an emphasis on cost-effective and sustainable anesthesia practices by reducing the usage of desflurane and substituting it with sevoflurane.

Asia-Pacific is expected to grow at the fastest CAGR of 7.5% from 2026 to 2035, because of its largest and aging population in the world, leading to a surge in surgical procedures in every specialty and rapid expansion in the healthcare infrastructure. China dominated the market in Asia-Pacific owing to its huge population base, rapidly growing hospital infrastructure, and significant efforts by the government to update anesthesia standards and discontinue the usage of older and harmful inhalation anesthetics. India is a significant contributor to the market due to the rapid growth of the middle-class population, an increase in the number of private chain hospitals, an increasing number of ambulatory surgery centers, and an increase in the use of sevoflurane due to the shift to modern anesthetic practices.

Europe held the second-largest market share of 28% in 2025, owing to the high number of surgeries carried out in this region, a well-developed public healthcare system, and a high level of environmental consciousness, which have accelerated the phase-out of desflurane and increased the popularity of sevoflurane. Germany led the market in Europe as it is a significant center of production and distribution of medical devices and pharmaceutical products, and has a significant presence of an advanced hospital network, which creates a constant demand for sevoflurane. The UK market is driven by initiatives by the National Health Service (NHS), which promotes cost-effectiveness and environmental consciousness and has phased out desflurane in favor of sevoflurane through government-endorsed initiatives.

Sevoflurane Market Coverage

Top Companies in the Sevoflurane Market

Baxter International, AbbVie Inc., and Fresenius Kabi AG are some of the key players that are global suppliers of sevoflurane as an inhalation anesthetic for induction and maintenance of general anesthesia. Halocarbon Life Sciences and Piramal Pharma Limited are top specialty manufacturers of sevoflurane, along with other volatile anesthetics. Lunan Pharmaceutical Group, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Troikaa Pharmaceuticals Ltd. are key Asian manufacturers of sevoflurane that compete in both domestic and international markets. Maruishi Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. are Japanese manufacturers of sevoflurane that serve the domestic market. Sandoz Group AF and Mylan (Viatris) are global generic pharmaceutical companies offering sevoflurane as a part of their portfolio of hospital injectables.

Segments Covered in This Report

By Product Type

• Branded Sevoflurane
• Generic Sevoflurane
• High-Purity Sevoflurane
• Pediatric Grade Sevoflurane
• Hospital Grade Sevoflurane

By Formulation

• Liquid Sevoflurane
• Stabilized Sevoflurane

By Application

• General Surgery
• Cardiovascular Surgery
• Orthopedic Surgery
• Neurological Surgery
• Pediatric Surgery
• Ambulatory Surgery
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Academic & Research Institutes

By Distribution Channel

• Direct Tender Sales
• Hospital Pharmacies
• Pharmaceutical Distributors
• Online Procurement Platforms

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8525

You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344